Richard Dickinson > Bristows LLP > London, England > Lawyer Profile

Bristows LLP

Living Wage

Work Department

Commercial IP


Richard is a partner in the commercial IP team where his practice focuses on commercial transactions and advisory work that involves the development, exploitation and protection of IP rights.

Richard’s practice focuses on commercial transactions and advisory work that usually involve the development, exploitation and protection of IP rights at their core, across a range of sectors. These include life sciences, technology, media and entertainment, consumer and retail.

With over 25 years’ experience, his work has included licensing, distribution, manufacturing and supply agreements, as well as related commercial contracts and advising on the relevant IP aspects in corporate deals. Much of Richard’s work involves cross-border projects.

Richard has a scientific background and has also worked on secondment with in-house legal teams, both as an associate and as a partner.

Richard joined Bristows in January 2020 as a partner in the commercial IP/IT team.


Qualified 1996, Partner 2005. At Bristows since 2020


BSc (Hons) Biochemistry, University of Bristol
Post Graduate Diploma in Law, University of the West of England, Bristol
Legal Practice Course, University of the West of England

Lawyer Rankings

London > Corporate and commercial > Commercial contracts

With substantial expertise in the technology and healthcare sectors, Bristows LLP handles a broad range of commercial mandates, with particular experience in the commercial exploitation of IP rights, the competition and tax elements of technology deals, and regulatory mandates. The team’s healthcare knowledge has recently led to a raft of Covid-related work; the group advised the University of Oxford on a research collaboration and licence agreement with AstraZeneca for a vaccine. Matthew Warren leads the practice, which also includes recently promoted partner Claire Smith and Richard Dickinson, who joined from Arnold & Porter in 2020.

London > TMT (technology, media and telecoms) > Intellectual property: trade marks, copyright and design

The team at Bristows LLP has exceptional capabilities in trade mark litigation, with Jeremy Blum and co-head Simon Clark leading on high-profile passing off disputes for international entertainment, pharmaceuticals and retail companies. Clark also takes the lead on digital copyright, design and data disputes, including recent law-making litigation surrounding the use of website cookies. Paul Jordan specialises in brand protection work for creative and print media companies; co-head Ian Gruselle’s trade mark portfolio practice contributes to the 360-degree approach on this front. The extensive transactional IP bench consists of devoted partners Claire Smith, co-head Matthew Warren and Richard Dickinson. The firm advises leading global brands in luxury retail, consumer electronics, FMCG and hi-tech on licensing and collaboration agreements, R&D and brand exploitation exercises. Paul Walsh has retired from the partnership, but remains at the firm on a consultancy basis.

London > TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious)

Bristows LLP fields one of the most extensive patent litigation benches in Europe, housing impressive names including co-heads Andrew Bowler and Myles Jelf (‘Absolutely exceptional. Hugely experienced in international patent litigation‘). Other key names include Dominic Adair, ‘brilliant tacticianBrian Cordery, Liz Cohen, Robert Burrows and Gemma Barrett. Life sciences is a focus, however the technical backgrounds of the ‘exceptionally smartJames Boon, Richard Pinckney, associate Naomi Hazenberg and others are also applied to disputes in the telecoms, aerospace and renewable energy sectors. The transactional offering led by Matthew Warren (who runs high-value licensing agreements in the life sciences and technology sectors) continues to expand: Richard Dickinson and numerous associates joined from Arnold & Porter, further strengthening the life sciences expertise. Also a highly regarded patent transactions lawyer, Claire Smith is a leader in the field of DNA-sequencing technology. The team advised on the University of Oxford’s landmark R&D agreement with AstraZeneca to manufacture and commercialise a Covid-19 vaccine.

London > TMT (technology, media and telecoms) > Media and entertainment (including media finance)

Bristows LLP leverages the firm’s impressive technology, data privacy and intellectual property expertise to act on contentious and non-contentious matters for clients across the media and entertainment sector. Paul Jordan handles advertising, marketing law and brand protection work. He co-heads the practice with technology expert Mark Watts, who is noted for his particular expertise in data privacy. Commercial disputes partner Mark Brown has a strong profile among clients in the gaming industry. In addition, other key individuals include Richard Dickinson and of counsel Greg Ruback, who joined from Arnold & Porter and Paramount Pictures respectively in 2020. Senior associate Andrew Butcher is also recommended.

London > Industry focus > Life sciences and healthcare

The ‘exceptionally high quality’ life sciences practice at Bristows LLP offers a cohesive multi-disciplinary team advising on a broad range of complex regulatory and transactional work. The team is highly recommended for multi-jurisdictional M&A and investment. Liz Cohen has a strong record of coordinating cross-border patent litigation, and is known for handling cases involving sophisticated scientific concepts. She jointly heads the group with Richard Dickinson, who focuses on IP and commercial transactions, particularly licensing, distribution, manufacturing and supply agreements. Claire Smith is similarly noted for her commercial IP experience, while Robert Burrows‘ PhD in molecular genetics equips him to undertake technically challenging cases. Alex Denoon leads the firm’s stand-out regulatory practice, and is particularly sought after by clients specialising in disruptive technologies such as genomics, companion diagnostics, cell therapies and tissue and cells borderline products.